Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effects of PEX010 Psilocybin Capsules for Patients with Prolonged Grief Disorder

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment for Prolonged Grief Disorder, a condition where individuals experience intense and persistent grief that disrupts their daily life. The treatment being tested is called PEX010 Psilocybin Capsules, which contain a substance derived from a type of mushroom known as Psilocybe cubensis. The study will use two different doses of the capsules: one with 1 mg of psilocybin and another with 25 mg of psilocybin.

The purpose of the study is to see if taking the PEX010 Psilocybin Capsules can help reduce the symptoms of prolonged grief disorder. Participants in the study will be randomly assigned to receive either the psilocybin capsules or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo during the trial.

Throughout the study, participants will have a dosing session where they will take the capsules. The researchers will then monitor the participants to see if there is a significant reduction in their grief symptoms, as measured by a specific scale used to assess prolonged grief disorder. The study aims to provide valuable information on whether psilocybin can be an effective treatment for those struggling with prolonged grief.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, an initial visit is scheduled. During this visit, a comprehensive health assessment is conducted. This includes reviewing medical history, performing an electrocardiogram (ECG), and conducting various laboratory tests. These tests check levels of electrolytes, kidney function, blood sugar, blood cell counts, thyroid function, and liver health. The results are evaluated by a study physician to confirm good health status.

  2. Step 2

    Randomization

    Participants are randomly assigned to receive either a low dose or a high dose of the study medication, PEX010 Psilocybin Capsules. This process is double-blind, meaning neither the participant nor the study team knows which dose is being administered.

  3. Step 3

    Dosing session

    Participants attend a dosing session where they receive the assigned dose of PEX010 Psilocybin Capsules. The medication is taken orally in capsule form. The low dose contains 1 mg of psilocybin, while the high dose contains 25 mg of psilocybin. The session is supervised by the study team to ensure safety and comfort.

  4. Step 4

    Follow-up assessments

    After the dosing session, follow-up assessments are conducted to monitor the participant's response to the medication. These assessments focus on evaluating changes in the participant's grief symptoms using the revised prolonged grief disorder scale, known as the PG13-R scale.

  5. Step 5

    End of trial

    The trial is expected to conclude by April 1, 2028. Participants will have completed all required assessments and dosing sessions by this time. The study team will analyze the data to determine the effectiveness of the medication in reducing symptoms of prolonged grief disorder.

Who can join the trial?

5 criteria

  • The person must have given their written consent to participate in the trial.
  • The person must have a PG13-R score of 30 or higher. PG13-R score is a measure used to assess prolonged grief disorder.
  • The person must be in good health as determined by their medical history, an ECG (a test that checks the heart's electrical activity), and lab tests. These lab tests will check various things in the blood, such as electrolytes (sodium, potassium, chloride, magnesium, calcium, phosphate), kidney function (GFR, creatinine), blood sugar (glucose), blood cell counts (complete blood count, hemoglobin, MCV, white blood cells, platelets), thyroid function (TSH), and liver function (total bilirubin, ALP, AST, ALT, GGT). The final decision will be made by a study doctor.
  • The person can be of any gender.
  • The person must not be part of a vulnerable population.

Who cannot join the trial?

3 criteria

  • Patients who are not diagnosed with prolonged grief disorder cannot participate.
  • Individuals who are not within the specified age range cannot participate. The age range includes young adults and middle-aged adults.
  • Participants must not belong to any vulnerable population groups.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

PEX010 is a medication being tested in this clinical trial to see if it can help people who are experiencing prolonged grief disorder. This condition involves intense and long-lasting feelings of grief that can interfere with daily life. The trial aims to find out if taking PEX010 can reduce these feelings and improve the well-being of those affected. Participants will receive this medication during the trial to see if it helps them feel better and cope with their grief more effectively.

What is already known about the treatment

PEX010 – PEX010 is administered in a controlled setting, typically as an oral medication, and is currently being studied in clinical trials for its potential to help individuals with prolonged grief disorder. This medication is still under investigation, and its effectiveness and safety are being evaluated in medical research. The main goal of PEX010 is to reduce symptoms associated with prolonged grief, which is a condition where individuals experience intense and persistent grief that disrupts their daily life. At the molecular level, PEX010 is believed to work by modulating certain brain chemicals that are involved in mood and emotional regulation, although the exact mechanism is still being studied. It is classified pharmacologically as a potential therapeutic agent for mental health conditions related to grief.

Investigated diseases

Prolonged grief disorder – Prolonged grief disorder is a condition characterized by an intense and persistent longing or yearning for a deceased person, usually a close loved one. This condition goes beyond normal grief and can significantly disrupt daily life. Individuals with this disorder may experience emotional numbness, difficulty accepting the death, and a sense of disbelief. They might also feel a diminished sense of identity or purpose, as well as a lack of interest in engaging with others or in activities they once enjoyed. The symptoms persist for an extended period, typically more than 12 months for adults and 6 months for children. This disorder can lead to significant emotional distress and challenges in functioning in social, occupational, or other important areas.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-518218-24-00Estimated enrolment60 patientsSponsorLinkopings Universitet

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.